Table 4.
Comparison of cutaneous COVID-19 vaccine reactions to the Moderna vaccine and the Pfizer vaccine in our study to those in a previously published study
| Cutaneous reaction | Present study | McMahon et al. [1] | ||||
|---|---|---|---|---|---|---|
| Overall, n (%) | Moderna, n (%) | Pfizer, n (%) | Overall, n (%) | Moderna, n (%) | Pfizer, n (%) | |
| Total number | 67,273 | 45,316 | 18,622 | 414 | 343 | 71 |
| Injection-site reactiona | 37,559 (59.73) | 31,349 (70.40) | 6210 (33.84) | 202 (48.8) | 186 (54.2) | 16 (22.5) |
| Urticaria | 22,463 (32.11) | 10,573 (23.74) | 9431 (51.39) | 37 (8.9) | 23 (6.7) | 14 (19.7) |
| Papular rash | 3083 (4.90) | 2034 (4.57) | 1049 (5.72) | NR | NR | NR |
| Angioedema | 885 (1.26) | 386 (0.87) | 406 (2.21) | 6 (1.4) | 5 (1.5) | 1 (1.4) |
| Petechiae | 830 (1.19) | 301 (0.68) | 379 (2.07) | 4 (0.97) | 3 (0.87) | 1 (1.4) |
| Vesicular rash | 793 (1.13) | 278 (0.62) | 362 (1.97) | 10 (2.4) | 5 (1.5) | 5 (7.0) |
| Psoriasis | 490 (0.70) | 182 (0.41) | 243 (1.32) | NR | NR | NR |
| Pityriasis rosea | 257 (0.37) | 94 (0.21) | 138 (0.75) | 4 (0.97) | 1 (0.29) | 3 (4.2) |
| Contact dermatitis | 224 (0.32) | 83 (0.19) | 108 (0.59) | 6 (1.4) | 4 (1.2) | 2 (2.8) |
| Morbilliform rash | 202 (0.29) | 88 (0.20) | 91 (0.50) | 27 (6.5) | 18 (5.2) | 9 (12.7) |
| Erythema multiforme | 188 (0.27) | 123 (0.28) | 53 (0.29) | 3 (0.72) | 3 (0.87) | 0 (0) |
| Lichen planus | 96 (0.14) | 38 (0.09) | 49 (0.27) | NR | NR | NR |
| Chilblains | 65 (0.09) | 29 (0.07) | 36 (0.20) | NR | NR | NR |
| Granuloma annulare | 65 (0.09) | 30 (0.07) | 28 (0.15) | NR | NR | NR |
| Cutaneous vasculitis | 53 (0.08) | 20 (0.04) | 26 (0.14) | 3 (0.72) | 2 (0.58) | 1 (1.4) |
| Erythromelalgia | 20 (0.03) | 7 (0.02) | 12 (0.07) | 14 (3.4) | 11 (3.2) | 3 (4.2) |
NR not reported
aErythema, pain, swelling